Manufacturing & Packaging

Marks the latest big pharma partnership for CureVac around its Covid vaccine candidate, CVnCoV

In extension of J&J agreement, deal provides manufacturing facilities for Covid-19 vaccine production

Rivals will team up in order to accelerate supply

Joins network of manufacturers contributing efforts to increase supply

Joins UK consortium to help efficiently manufacture oral solid dosage medication

Company says it will be able to produce an estimated 12 million doses per month

The importance of thinking strategically about the infrastructure and foresight needed to scale up CGTs—not as treatments of last resort, but first choice

Lab development project features 9,000-square-foot expansion

Results address concerns surrounding bulk passive pharma packaging

$180M collaboration aims to introduce multiple vaccine candidates in 2022

Two-dose COVAXIN currently under EUA in India

Rating for packaging supplier highlights its commitment to sustainable practices and corporate social responsibility

In Phase III at the moment, mRNA dose will be produced at Bayer's Wuppertal, Germany facility

Production expected to begin in the second quarter

Boston-area location will be fully operational in Q4

Latest air cargo collaboration provides pandemic response support

Unnamed US facility will increase company's manufacturing capacity

These organizations are encouraged to consider all alternatives when planning their packaging, serialization and validation strategies

Liquid pharmaceuticals can serve as needed alternatives in hospitals and other care settings

Acquisition grows company's chemical manufacturing and R&D network

Strike partnership deal focused on manufacturing and commercialization services

Carlsbad structure will house material for cell and gene-based therapies

Resource aims to boost tech aptitude in temperature-controlled packaging field

As it awaits status of Moderna vaccine, Swedish CDMO receives tender

A one-on-one with Fabian Gerlinghaus, co-founder and CEO of Cellares, who discusses the quest to overcome bottlenecks in industrial scale cell therapy manufacturing